“PIK”ing the Right Patients for Adjuvant Aspirin Therapy for Colorectal Cancer
Observational studies demonstrate that aspirin use after diagnosis of colorectal cancer, particularly tumors with mutated PIK3CA, improves outcomes. However, randomized controlled trial data are lacking. In this issue, we discuss the SAKK 41/13 adjuvant aspirin randomized controlled trial results in context of other adjuvant aspirin trials and emerging data on potential mechanisms of action. See related article by Güller et al., p. 3142.
Authors
- David A. Drew (ORCID: https://orcid.org/0000-0002-8813-0816)
- Andrew T. Chan (ORCID: https://orcid.org/0000-0001-7284-6767)
- Jonathan M. Downie (ORCID: https://orcid.org/0000-0002-5424-4401)
Institutions
- Massachusetts General Hospital (US)
Publication Details
- Journal
- Clinical Cancer Research
- Published
- 2025-05-29
- DOI
- https://doi.org/10.1158/1078-0432.ccr-25-0953
- Primary Topic
- Inflammatory mediators and NSAID effects
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- V Foundation for Cancer Research
- National Institutes of Health